The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 ...

There isn't a cure for the condition, but doctors may recommend medications to slow down the progression of the disease or ...

Diabetes is a common, lifelong condition that occurs when the pancreas doesn't produce enough insulin, or when the body is unable to effectively use the insulin it produces ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

An estimated 42 million people in India suffer from thyroid problems, an autoimmune condition that has grown very common. The most frequent cause is thought to be iodine deficiency brought on by ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

We are aware of reports regarding supply issues of insulin in the UK. Some of these reports are of insulins that are being discontinued and some are where there is a temporary shortage. Here’s the ...

A high-sugar diet may increase the risk of weight gain, obesity, cancer, and potentially accelerate tumor growth.

This article looks at the current understanding of insulin resistance and its role as a risk factor for diabetes and other conditions. It also describes the signs and symptoms of insulin ...

About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...